<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-02-02">2 February 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Caplin</surname></persName>
							<email>m.caplin@ucl.ac.uk</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Neuroendocrine Tumour Unit</orgName>
								<orgName type="institution" key="instit2">Royal Free Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Nuclear Medicine, Endocrine Cancer and Interventional Radiology</orgName>
								<orgName type="department" key="dep2">Institut Gustave Roussy</orgName>
								<orgName type="institution">Université Paris Sud</orgName>
								<address>
									<settlement>Villejuif Cedex</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">NET Center</orgName>
								<orgName type="institution" key="instit1">Umbria Regional Cancer Network</orgName>
								<orgName type="institution" key="instit2">Università degli Studi di Perugia</orgName>
								<address>
									<settlement>Perugia</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Filosso</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">University of Torino</orgName>
								<address>
									<settlement>Torino</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Garcia-Yuste</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">University Clinic Hospital</orgName>
								<address>
									<settlement>Valladolid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Lim</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">Imperial College and The Academic Division of Thoracic Surgery</orgName>
								<orgName type="institution">The Royal Brompton Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="laboratory">Endocrine Oncology Unit</orgName>
								<orgName type="institution">University Hospital</orgName>
								<address>
									<settlement>Uppsala</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Pelosi</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Dipartimento di Scienze Biologiche e Cliniche Luigi Sacco</orgName>
								<orgName type="institution" key="instit1">Fondazione IRCCS Istituto Nazionale dei Tumori</orgName>
								<orgName type="institution" key="instit2">Università degli studi di Milano</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Perren</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University of Bern</orgName>
								<address>
									<settlement>Bern</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Rossi</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Neuroendocrine Tumour Unit</orgName>
								<orgName type="institution" key="instit2">Royal Free Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Pathophysiology and Transplantation</orgName>
								<orgName type="laboratory">Gastroenterology and Endoscopy Unit</orgName>
								<orgName type="institution" key="instit1">Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</orgName>
								<orgName type="institution" key="instit2">Università degli Studi di Milano</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Travis</surname></persName>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="middle">Martyn</forename><surname>Caplin</surname></persName>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Memorial Sloan Kettering Cancer Center</orgName>
								<address>
									<settlement>New York</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Neuroendocrine Tumour Unit</orgName>
								<orgName type="institution" key="instit2">Royal Free Hospital</orgName>
								<address>
									<addrLine>Pond Street</addrLine>
									<postCode>NW3 2QG</postCode>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-02-02">2 February 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">B039A3A4CADF40C5C94A028F150FA09E</idno>
					<idno type="DOI">10.7892/boris.70201|downloaded:18.5.2022</idno>
					<note type="submission">Received 6 April 2014; revised 8 January 2015; accepted 22 January 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:28+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>pulmonary</term>
					<term>carcinoid</term>
					<term>bronchial</term>
					<term>typical carcinoid</term>
					<term>atypical carcinoid</term>
					<term>neuroendocrine tumor</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.</s><s>Lancet 2011; 377: 813-822.</s><s>80. Logothetis CJ, Basch E, Molina A et al.</s><s>Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletalrelated events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.</s><s>Lancet Oncol 2012; 13: 1210-1217.</s><s>81.</s><s>Fizazi K, Scher HI, Miller K et al.</s><s>Effect of enzalutamide on time to first skeletalrelated event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.</s><s>Lancet Oncol 2014; 15: 1147-1156.</s><s>82.</s><s>Sartor O, Coleman R, Nilsson S et al.</s><s>Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>literature search methods</head><p><s>The Oxford Centre for Evidence-Based Medicine's Levels of Evidence (2011; Centre for Evidence-Based Medicine, Levels of Evidence, http://www.cebm.net/index.aspx?o¼1025) were used to evaluate the evidence cited in this consensus document, and outcomes were additionally graded according to the modified Grading of Recommendations Assessment Development and Evaluation Working Group 2007 (http://www.gradeworkinggroup.org/).</s><s>Bibliographical searches were carried out in PubMed for the terms 'pulmonary neuroendocrine tumors', 'bronchial neuroendocrine tumors', 'bronchial carcinoid tumors', 'pulmonary carcinoid', 'pulmonary typical carcinoid', 'pulmonary atypical carcinoid', 'pulmonary carcinoid and diagnosis', 'pulmonary carcinoid and treatment', 'pulmonary carcinoid and epidemiology', and 'pulmonary carcinoid and prognosis'.</s><s>For each term, the search was carried out without any filter in first instance, thereafter applying filters for publication type [Randomized, controlled trials (RCTs), Case Reports] and using the Mesh Terms 'Case-control Studies' and 'cohort studies'.</s><s>No language restriction was applied.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>literature search results</head><p><s>For the term 'pulmonary neuroendocrine tumors', we found 11 302 articles in total, 2669 case reports, 1028 cohort studies, 580 case-control studies, and 36 RCTs.</s><s>For the term 'bronchial neuroendocrine tumors', we found 1834 articles in total, 761 case reports, 233 cohort studies, and 124 case-control studies, while no RCT was available.</s><s>For the term 'bronchial carcinoid tumors', we found 1611 articles in total, 661 case reports, 224 cohort studies, and 119 case-control studies, while no RCT was available.</s><s>For the term 'pulmonary carcinoid', we found 3080 articles in total, 1027 case reports, 454 cohort studies, 274 casecontrol studies, and 5 RCTs.</s><s>For the term 'pulmonary typical carcinoid', we found 575 articles in total, 135 case reports, 131 cohort studies, 85 case-control studies, and 1 RCT.</s><s>For the term 'pulmonary atypical carcinoid', we found 576 articles in total, 137 case reports, 123 cohort studies, and 87 case-control studies, while no RCT was available.</s><s>For the terms 'pulmonary carcinoid and diagnosis', we found 2554 articles in total, 895 case reports, 421 cohort studies, 257 case-control studies, and 4 RCTs.</s><s>For the terms 'pulmonary carcinoid and treatment', we found 1420 articles in total, 539 case reports, 331 cohort studies, 185 casecontrol studies, and 3 RCTs.</s><s>For the terms 'pulmonary carcinoid and epidemiology', we found 339 articles in total, 17 case reports, 158 cohort studies, 109 case-control studies, and 1 RCT.</s><s>Finally, for the terms 'pulmonary carcinoid and prognosis', we found 192 articles in total, 7 case reports, 96 cohort studies, and 70 case-control studies, while no RCT was available.</s></p><p><s>We excluded in vitro and animal studies, and prioritized meta-analyses, systematic reviews, and RCTs where available.</s><s>We finally identified a total of 176 pertinent articles with the strongest level of evidence.</s><s>In more detail, we considered 54 articles for 'Epidemiology paragraph', 36 for 'Pathology paragraph', 35 for 'Diagnosis paragraph', 15 for 'Surgery paragraph', and <ref type="bibr">36 110</ref> for 'Medical therapy paragraph'.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>terminology issue</head><p><s>The term neuroendocrine (NE) neoplasm encompasses the whole spectrum of lung tumors characterized by NE morphology and differentiation <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>, including well-differentiated and poorly differentiated tumors.</s><s>The historical term carcinoid, either TC or AC for the subgroups of well-differentiated NET, is preferable over other proposed alternative names derived from the concept of either tumor grading <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>, tumor extension (localized versus metastatic) <ref type="bibr" target="#b5">[6]</ref> or tumor behavior <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>This is because TC and AC are identified as unique clinico-pathological traits that separate it clearly from the remaining ( poorly differentiated) NET which includes the high-grade large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) <ref type="bibr" target="#b1">[2]</ref>.</s><s>In the following text, the terms PC and pulmonary NET will be used.</s></p><p><s>epidemiology PCs are rare tumors with an age-adjusted incidence rate ranging from 0.2 to 2/100 000 population/year in both US and European countries <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref>.</s><s>There has been an increasing prevalence over the last 30 years, 6% per year, regardless of confounding demographic factors, such as age, gender, race, and stage distribution <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>This tendency of PCs to increase over time is likely due to improved awareness <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref> and increased use of special immunohistochemistry (IHC) stains <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b26">27]</ref>.</s><s>PCs prevail slightly in women over men, in whites over blacks, or other ethnicities including Hispanic and Asian people <ref type="bibr">[10-14, 16, 18-23, 28-31]</ref>.</s><s>They occur in the fourth to sixth decades of life, with a younger mean age <ref type="bibr">(45 years)</ref> for TC and one decade later for AC <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref>. PCs are the most common primary lung neoplasm in children <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b34">35]</ref> and late adolescents <ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref>, with TC prevailing by far over AC.</s></p><p><s>The prevalence of pulmonary NETs compared with the main subtypes of lung cancer has remained relatively unchanged except for SCLC, which has shown decreasing incidence, at least in men <ref type="bibr" target="#b9">[10]</ref>, probably due to major changes in smoking habits <ref type="bibr" target="#b26">[27]</ref>.</s><s>Currently, PCs account for 1-2% of all invasive lung malignancies, roughly corresponding to one-fourth to one-third of all well-differentiated NETs throughout the body.</s><s>The large majority of poorly differentiated NE carcinomas (NECs), accounting for 90%, develop in the lung <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40]</ref> likely due to their strong association with smoking.</s></p><p><s>The majority of PC patients develop in never or current light smokers <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref>, although more AC patients are current or former smokers than TC patients <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b43">44]</ref>.</s><s>In contrast, SCLC and LCNEC are associated with heavy smokers <ref type="bibr" target="#b1">[2]</ref>.</s><s>PCs may also develop in patients with a previous history of cancer (especially skin, urogenital, and respiratory tract) <ref type="bibr" target="#b29">[30]</ref>, although the frequency of these tumors in the population may account for this association and PC may be detected due to increased surveillance.</s><s>PCs are usually sporadic lesions; however, rare familial cases have been reported <ref type="bibr" target="#b45">[46,</ref><ref type="bibr" target="#b46">47]</ref>.</s><s>Up to 5% of patients with multiple endocrine neoplasia type 1 (MEN1) harbor PCs, usually TC with a smaller number of AC <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref>. Clinical evolution of these familial tumors is generally favorable, but lifethreatening tumors are also on record <ref type="bibr" target="#b45">[46]</ref>.</s></p><p><s>The ratio between TC and AC is about 8-10 : 1, so AC is the most uncommon of the lung NETs <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b51">52]</ref>, even though some recent studies have described a relative excess of AC diagnoses <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b29">30]</ref>.</s><s>Due to inconsistency in AC reporting or coding, data from cancer registries are not generally reliable for information about TC versus AC including data from the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program because peer review of the histological slides is not possible <ref type="bibr" target="#b52">[53]</ref>.</s></p><p><s>The decreased survival of PCs observed over the last 30 years is likely due to an increased recognition of AC over TC <ref type="bibr" target="#b26">[27]</ref>.</s><s>This distribution is closely in keeping with the current histological classification, as TCs are metastatic in up to 15% of cases, usually to regional lymph nodes, with a median time to recurrence of 4 years, whereas ACs are regionally or distantly metastatic in up to one half of tumors with a median time to recurrence of 1.8 years.</s><s>However, for both TC and AC, recurrence may not occur until many years later, hence the need for long-term surveillance <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b53">54]</ref>.</s></p><p><s>PCs are also detected in lung cancer screening low-dose computed tomography (CT) trials, especially at the baseline with a prevalence of TC over AC <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>On annual repeat controls, AC tends to prevail probably because of its inherent greater malignant potential <ref type="bibr" target="#b24">[25]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>pathology classification</head><p><s>PCs are classified according to the widely agreed WHO 2004 scheme <ref type="bibr" target="#b1">[2]</ref>, i.e.</s><s>TC and AC.</s><s>The term of carcinoid has been maintained during all WHO classifications published since 1967, even though the diagnostic criteria separating TC from AC were only introduced in the 1999 WHO classification and subsequently maintained in the 2004 WHO classification <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b54">55]</ref>.</s><s>Many other classification schemes and terminologies have been proposed over time, either introducing a concept of tumor grading <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b55">56]</ref>, applying different thresholds to current diagnostic criteria <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b56">57]</ref>, or generalizing the taxonomy used in GEP NETs <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b57">58,</ref><ref type="bibr" target="#b58">59]</ref>.</s><s>These different proposals have not gained general acceptance yet because of the lack of clear clinical evidence for significant advantages over the current WHO classification.</s><s>The recent proposal of tumor grading based on a combination of KI-67 labeling index, mitotic rate, and necrosis may be of clinical importance if it can be validated <ref type="bibr" target="#b55">[56]</ref>.</s></p><p><s>PCs are tumors with NE morphology and differentiation, which are deemed to derive from, or differentiate toward, the mature NE cells of the pulmonary diffuse NE system <ref type="bibr" target="#b59">[60]</ref><ref type="bibr" target="#b60">[61]</ref><ref type="bibr" target="#b61">[62]</ref>.</s><s>They encompass low (TC) to intermediate (AC) malignant lesions, which do not have any causative relationship or common genetic/epidemiologic/clinic traits with SCLC and LCNEC <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b62">63]</ref>.</s><s>In particular, PCs as a whole are well-differentiated tumors as opposed to SCLC and LCNEC, with TC sharing some homologies with Grade 1 NETs and AC some homologies with Grade 2 NETs of the GEP tract.</s><s>SCLC and LCNEC widely correspond to the Grade 3 NEC category of the GEP tract <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b63">64]</ref>.</s></p><p><s>TC has fewer than 2 mitoses/2 mm 2 and absence of necrosis, and AC has 2-10 mitoses/2 mm 2 and/or foci of punctate necrosis.</s><s>SCLC and LCNEC have more than 10 mitoses/2 mm 2 (usually greater than 50/2 mm 2 ) and extensive geographic necrosis <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b54">55,</ref><ref type="bibr" target="#b65">65]</ref>.</s><s>A mitotic count should be carried out in hotspot areas.</s><s>A report that IHC methods may be useful to highlight mitotic figures needs further confirmation <ref type="bibr" target="#b66">[66]</ref>.</s><s>Diagnostic criteria regarding the assessment of cell features (dimension of tumor cells, prominence of nucleoli, and chromatin pattern) are used to better classify poorly differentiated NECs (SCLC and LCNEC), whereas they do not serve to distinguish TC and AC.</s><s>Molecular studies have shown differences between TC and AC and high-grade NECs <ref type="bibr" target="#b67">[67]</ref>.</s><s>There are limitations regarding reproducibility in differences of counting mitosis/ area.</s><s>Since the difference of one mitoses (e.g. from 10 to 11) makes an arbitrary difference in diagnostic category from AC to LCNEC, further studies are mandatory.</s></p><p><s>Combined tumors have been described for both SCLC and LCNEC <ref type="bibr" target="#b1">[2]</ref>, whereas the association of PC with conventional NSCLC is extremely rare.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>grading system</head><p><s>Grading of NE lung tumors is inherently present in the current classification scheme <ref type="bibr" target="#b1">[2]</ref>.</s><s>Considerable clinical and epidemiologic data exist to validate this grading system resulting in a pathologic four-tier and clinical three-tier spectrum of NE-differentiated tumors characterized by aggressiveness: TCs are low-grade malignant; AC intermediate-grade malignant; and LCNEC and SCLC are high-grade malignant NETs <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>.</s><s>SCLC is so common to the lung to make it a distinctive entity with its own epidemiologic, genetic, clinical, and pathologic traits.</s><s>However, establishing a grading system in lung NETs independent of histology could be clinically useful, although the criteria for grading lung NET may be different from those used for GEP NETs <ref type="bibr" target="#b69">[68]</ref>.</s><s>Such a grading system could include Ki-67, mitotic rate, and necrosis as recently proposed; however, there is a significant need for further validation studies <ref type="bibr" target="#b55">[56]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ki-67 immunoreactivity</head><p><s>Ki-67 antigen IHC (the product of MKI67 gene mapping to 10q26.2 gene involved in cell proliferation), which is generally carried out by using the clone Mib-1 and mostly expressed as labeling index ( percentage of positive tumor cells or labeling index), has a value in distinguishing PCs from high-grade NETs in small crushed biopsies <ref type="bibr" target="#b70">[69]</ref>.</s><s>However, Ki-67 expression does not reliably separate TC from AC, much less SCLC from LCNEC, better than the existing 2004 WHO histological criteria <ref type="bibr" target="#b1">[2]</ref>.</s><s>Ki-67 may play a role in predicting prognosis on resected specimens of PCs; however more data are needed to determine the utility in lung NETs <ref type="bibr" target="#b55">[56,</ref><ref type="bibr" target="#b69">68,</ref><ref type="bibr" target="#b71">[70]</ref><ref type="bibr" target="#b72">[71]</ref><ref type="bibr" target="#b73">[72]</ref> as opposed to GEP NETs where Ki-67 labeling index is an integral part of the current grading system <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b74">[73]</ref><ref type="bibr" target="#b75">[74]</ref><ref type="bibr" target="#b76">[75]</ref>.</s><s>Consensus regarding the optimal methods to adopt for assessing Ki-67 labeling index (digital image analysis, manual counting, eyeball estimation, and number of cells) is still lacking <ref type="bibr" target="#b76">[75]</ref>, even though some studies pointed to consider manual counting of at least 2000 cells in hotspot histological fields <ref type="bibr" target="#b51">[52,</ref><ref type="bibr" target="#b72">71,</ref><ref type="bibr" target="#b73">72,</ref><ref type="bibr" target="#b77">76,</ref><ref type="bibr" target="#b78">77]</ref>.</s><s>A high overall agreement of manual Ki-67 labeling index evaluation and an automated assessment method upon scanned slides have recently substantiated the value, reproducibility, and ease of Ki-67 labeling index upon manual mitotic counting <ref type="bibr" target="#b55">[56,</ref><ref type="bibr" target="#b79">78]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>tumor staging</head><p><s>Tumor staging of PCs is recommended according to the Union Internationale Contre le Cancer/American Joint Committee on Cancer (UICC/AJCC) 7th ed.</s><s>TNM system <ref type="bibr" target="#b52">[53,</ref><ref type="bibr" target="#b74">73]</ref>, although it will be necessary to refine descriptive categories according to tumor size, multicentricity, or other components of T, N, and M factors to be meaningful also in PCs [International Association for the Study of Lung Cancer (IASLC) Lung Cancer Perspective Staging Project].</s><s>Resection margins should be indicated, measuring the distance from the tumor edge to guarantee radical excision on surgical specimens <ref type="bibr" target="#b80">[79]</ref>.</s><s>Long-term studies, however, are needed to assess the risk and rate of relapse for R1 resection.</s><s>Most cases of multiple carcinoids are synchronous primaries rather than intrapulmonary metastases, particularly in the setting of Diffuse IdioPathic NeuroEndocrine Cell Hyperplasia (DIPNECH) <ref type="bibr" target="#b52">[53]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>other pathology information</head><p><s>The occurrence of NE cell hyperplasia in the surrounding lung tissue should be accurately documented <ref type="bibr" target="#b1">[2]</ref>.</s><s>This may require representative sampling of the non-neoplastic lung surrounding resected carcinoid tumors.</s><s>Most cases of NE hyperplasia represent an incidental finding in the non-neoplastic lung tissue adjacent to 25% of excised carcinoid tumors <ref type="bibr" target="#b81">[80]</ref>.</s><s>It is defined by the growth of NE cells proliferating in single cells and clusters within the bronchial epithelium.</s><s>Nodular NE cell proliferations measuring &lt;0.5 cm are termed 'tumorlets' and they typically show no mitoses, no necrosis, and a low Ki-67 labeling index <ref type="bibr" target="#b1">[2]</ref>, but may be detected on CT scan as subcentimeter multiple lung nodules.</s><s>Incidental NE cell hyperplasia is relatively common, but DIPNECH is extremely rare and is characterized by widespread NE cell hyperplasia and tumorlets.</s><s>It is regarded as a pre-invasive lesion associated with some risk of developing TC or AC, which can be multiple <ref type="bibr" target="#b50">[51,</ref><ref type="bibr" target="#b82">[81]</ref><ref type="bibr" target="#b83">[82]</ref><ref type="bibr" target="#b84">[83]</ref><ref type="bibr" target="#b85">[84]</ref>.</s><s>In DIPNECH, a high-resolution CT scan with an expiration study may show not only multiple nodules due to the tumorlets and carcinoid tumors, but it may show ground glass attenuation, bronchiectasis, and air trapping due to small airway obstruction <ref type="bibr" target="#b86">[85]</ref>.</s></p><p><s>IHC demonstration of few selected markers [chromogranin A, synaptophysin and/or CD56, cytokeratins, and thyroid transcription factor-1 (TTF1)] may help to confirm NE and epithelial differentiation, especially in limited diagnostic material <ref type="bibr" target="#b1">[2]</ref>.</s><s>These immunostains do not distinguish TC from AC, even though the latter may present with more irregular distribution of NE markers.</s><s>TTF1 is more commonly found in peripheral PC and cytokeratins may assist in the diagnostic recognition of pulmonary paraganglioma <ref type="bibr" target="#b1">[2]</ref>.</s><s>The separation of PC from poorly differentiated NET, especially in limited diagnostic material, may be reliably made exploiting Ki-67 labeling index <ref type="bibr" target="#b69">[68]</ref>.</s><s>Immunostains for CDX-2, Islet1, TTF1 or specific hormones, and biogenic amines might be used to separate pulmonary NET from lung metastases of well-differentiated NET of other organs usually GEP in origin <ref type="bibr" target="#b87">[86,</ref><ref type="bibr" target="#b88">87]</ref>.</s><s>Breast or prostate cancer may exhibit NE differentiation, which may lead to diagnostic confusion with PC, when small biopsy and/or cytology samples A correct diagnosis in small biopsies and/or cytology samples requires careful attention to morphologic and IHC features.</s><s>TC and AC cannot be distinguished in biopsy and cytology, whereas AC may be suspected if mitoses or necrosis are present.</s><s>If a low proliferation activity is seen by Ki-67 labeling index, this may be helpful to exclude high-grade NECs even in small biopsy specimens <ref type="bibr" target="#b70">[69]</ref>.</s><s>Likewise, Ki-67 antigen IHC can effectively be used in cytology preparations to avoid misdiagnosis of poorly differentiated NET <ref type="bibr" target="#b70">[69]</ref>, whereas this procedure is not reliable for distinguishing TC from AC on conventional smears.</s><s>Immunostains for pan-endocrine markers to confirm the NE nature of tumor cells are useful in limited diagnostic material, whether biopsy or cytology.</s><s>Cytokeratins ( pool AE1/AE3) may be negative in up to 25% of PCs, but are consistently positive in SCLC and LCNEC.</s></p><p><s>pathology recommendations for the best practice • Current standard for classification and nomenclature is the 2004 WHO classification.</s><s>Relevant information also derives from the UICC/AJCC 7th edition TNM staging.</s><s>Other classifications are not recommended (Level of Evidence 3; Grade of recommendation B).</s></p><p><s>• Pathology report on pulmonary NETs should be shared by the multidisciplinary team along with oncologists, radiologists, nuclear medicine physicians, surgeons, pneumologists, and endocrinologists, where pathologists contribute to the clinical decision-making process (Level of Evidence 5; Grade of recommendation C).</s></p><p><s>• PCs as a whole are well-differentiated NETs as opposed to poorly differentiated SCLC and LCNEC, and include lowgrade malignant tumors, i.e.</s><s>TC, and intermediate-grade malignant tumors, i.e.</s><s>AC.</s><s>TC is closest to the G1 GEP NETs and AC is closest to the G2 GEP NETs.</s><s>SCLC and LCNEC generally correspond to the NEC category of the gastrointestinal tract according to the current WHO classification.</s><s>Diagnostic criteria, however, still rely primarily on histology (Level of Evidence 3; Grade of recommendation B).</s></p><p><s>• Separation of TC from AC requires a surgical specimen.</s><s>TC and AC cannot be reliably distinguished from each other in small biopsy and cytology (Level of Evidence 3; Grade of recommendation C).</s></p><p><s>• Mitotic count, necrosis, and Ki-67 labeling index should be indicated in the pathology reports of surgical specimens or biopsy samples for at least two reasons: (i) mitoses and necrosis are part of the classification criteria and permit cross-study comparisons; (ii) since the mitotic rate and Ki-67 proliferation index impact on survival even within AC (Level of Evidence 3; Grade of recommendation C).</s></p><p><s>• There are at least four major issues regarding Ki- There are some difficulties in the generation of recommendations for imaging and surgery for PC because many patients present with a 'lung mass' rather than a preoperative diagnosis of a PC; thus, preoperative workup and imaging needs to be special articles Annals of Oncology pragmatic and shown to add value to justify any additional cost and delay to definitive surgical treatment.</s></p><p><s>Needless to say all patients should be discussed within a multidisciplinary tumor board with a specialist interest in PCs to establish the most appropriate management for patients (Figures <ref type="figure">1 and 2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>biochemical assessment</head><p><s>The baseline tests should be limited to renal function, calcium, glucose, and plasma chromogranin A measurements <ref type="bibr" target="#b92">[91]</ref><ref type="bibr" target="#b93">[92]</ref><ref type="bibr" target="#b94">[93]</ref>.</s><s>In syndromic patients, specific markers are measured, e.g.</s><s>24-h urine 5-hydroxyindoleacetic acid measurement in carcinoid syndrome <ref type="bibr" target="#b95">[94]</ref><ref type="bibr" target="#b96">[95]</ref><ref type="bibr" target="#b97">[96]</ref>.</s><s>Carcinoid syndrome is found in 2-5% of PCs, most often when liver metastases are present.</s><s>Cushing's syndrome is found in 1-6% of patients and measurements recommended include serum cortisol, 24 h urine free cortisol, and adrenocorticotropic hormone (ACTH).</s><s>Up to 40% of patients presenting with ectopic Cushings are found to have a PC.</s><s>Acromegaly due to ectopic growth hormone-releasing hormone (GHRH) or insulin-like growth factor 1 (IGF-1) is a rare association and serum growth hormone; GHRH and IGF-1 can be measured when clinically indicated.</s><s>Extremely rarely ectopic insulin secretion may be associated in patients presenting with recurrent hypoglycemic episodes.</s><s>The syndrome of inappropriate antidiuretic hormone secretion is found in 5% of patients with SCLC and rarely in PC <ref type="bibr" target="#b95">[94,</ref><ref type="bibr" target="#b97">96,</ref><ref type="bibr" target="#b98">97]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MEN1-associated forms</head><p><s>PC may be rarely associated with MEN1 syndrome (&lt;5% of patients) and should not be confused with a metastatic spread or a second cancer.</s><s>MEN1 is investigated by family history, clinical examination, and minimal laboratory screening including ionized calcium, intact parathyroid hormone, and prolactin <ref type="bibr" target="#b99">[98]</ref>.</s><s>If the familial history is suggestive of a MEN1 syndrome or a second MEN1 feature is present, e.g.</s><s>hyperparathyroidism, screening for MEN1 mutational analysis should be carried out <ref type="bibr" target="#b97">[96,</ref><ref type="bibr" target="#b100">99]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>radiological imaging at diagnosis</head><p><s>More than 40% of the cases may be incidentally detectable on a standard chest X-ray <ref type="bibr" target="#b101">[100]</ref>.</s><s>The gold standard is a contrast CT scan.</s><s>A standard lung CT acquisition technique is used.</s><s>A delay of 20 s between the injection of contrast and images acquisition is required to obtain a good contrast enhancement of mediastinal structures.</s><s>In patients in whom contrast is contraindicated, highresolution CT may be used <ref type="bibr" target="#b82">[81,</ref><ref type="bibr" target="#b95">94,</ref><ref type="bibr" target="#b96">95,</ref><ref type="bibr" target="#b102">101,</ref><ref type="bibr" target="#b103">102]</ref>.</s></p><p><s>The CT imaging features of a PC is often nonspecific and may have similar appearances to adenocarcinoma or an epidermoid lung carcinoma.</s><s>The most common appearance is a round or ovoid shape peripheral lung nodule with smooth or lobular margins <ref type="bibr" target="#b102">[101]</ref>.</s><s>PCs, however, are often highly vascular and typically enhance following intravenous contrast administration <ref type="bibr" target="#b103">[102]</ref>.</s><s>They tend to grow very slowly when compared with other types of lung cancer.</s></p><p><s>In central forms, PCs are most often associated with indirect signs of obstruction on CT such as atelectasis, air trapping, obstructive pneumonitis or rarely, bronchiectasis or lung abscess.</s></p><p><s>For DIPNECH, high-resolution CT with an expiration study is useful as it shows mosaic attenuation or air trapping in</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TNM staging</head><p><s>Patients should be staged according to the UICC 7th TNM classification.</s><s>Both conventional and scintigraphic imaging are used to stage PC patients.</s><s>N2 staging does not represent an absolute contraindication for surgery due to the indolent course of a significant number of patients.</s><s>Controversy exists on the optimum mode of preoperative staging in the mediastinum.</s><s>This is because of the lack of information and consensus on surgery for patients with mediastinal lymph node involvement, for example, in a recent survey by the European Society of Thoracic Surgeons, many surgeons across Europe would offer upfront surgery for patients with clinical N2 disease as long as the primary tumor was deemed to be resectable <ref type="bibr" target="#b31">[32]</ref>.</s><s>If that is the case, then it could be argued that no further invasive staging is required if initial nuclear imaging suggests N2 disease.</s><s>However, there are few studies which have analyzed in depth the reasons for the impact of the presence of lymph node involvement in the prognosis of PCs.</s><s>In the EMETNE's experience, most patients with TC who presented metastasis or local recurrence in follow-up were in stage I and more than 55% are alive after treatment.</s><s>Among the AC cases with this evolution, however, 66% had lymph node metastases, and 80% of them died after treatment because of the recurrence.</s><s>The analysis of these results enables us to confirm that nodal invasion demonstrates an obvious influence in the prognosis of AC <ref type="bibr" target="#b104">[103]</ref>.</s></p><p><s>Imaging is also crucial for determining distant metastases.</s><s>The most common sites of PC metastases are the liver, bones, and mediastinal lymph nodes <ref type="bibr" target="#b105">[104]</ref>.</s><s>Multiphase CT including arterial and portal phase or magnetic resonance imaging (MRI) with dynamic acquisition and diffusion-weighted sequences of the liver should be used for the detection of liver metastases <ref type="bibr" target="#b106">[105]</ref>.</s></p><p><s>CT with appropriate window setting may be useful to reveal bone metastases; however, MRI is the technique of choice for detection and characterization of bone metastases, especially of the spine.</s><s>Somatostatin receptor scintigraphy (SRS) and most recently SSTR positron emission tomography (PET) imaging may have a higher grade of sensitivity for bone metastases <ref type="bibr" target="#b108">[106,</ref><ref type="bibr" target="#b109">107]</ref> (see below).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>nuclear medicine techniques</head><p><s>Nuclear medicine techniques may play a role in the diagnosis since they are more specific than conventional imaging for TC and 'lower grade' AC and enable whole-body imaging for staging, and help to predict the response to peptide receptor radiotargeted therapy (PRRT).</s></p><p><s>Whole-body SRS with thorax single-photon emission CT (SPECT)/CT may be useful to determine the N and M stage at diagnosis in the preoperative phase.</s><s>Nearly 80% of the primary tumors, predominantly TC, may be visualized with this technique <ref type="bibr" target="#b80">[79,</ref><ref type="bibr" target="#b95">94,</ref><ref type="bibr" target="#b108">106,</ref><ref type="bibr" target="#b110">108]</ref>.</s><s>The SUV at fludeoxyglucose (FDG) PET is generally higher in AC with a higher proliferation index, thus demonstrating that FDG PET is helpful in determining the biology of PC <ref type="bibr" target="#b111">[109]</ref>.</s><s>FDG PET is the most sensitive technique for poorly differentiated forms (SCLC and LCLC) <ref type="bibr" target="#b112">[110,</ref><ref type="bibr" target="#b113">111]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>special articles Annals of Oncology</head><p><s>A study by Pattenden et al. <ref type="bibr" target="#b114">[112]</ref> reported the sensitivity and specificity of 18 F-FDG PET/CT for the diagnosis of mediastinal lymph node disease in 207 patients with TC and AC as 33 and 94%, respectively, suggesting that lymph node metastases cannot accurately be ruled out with a negative PET-CT in TC.</s><s>If treatment decisions are based on the N2 status, further mediastinal staging using either endobronchial ultrasound/endoscopy ultrasound fine needle aspiration or mediastinoscopy and lymph node biopsies will be required.</s></p><p><s>Whenever available, Gallium-68-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) somatostatin analog [SSA; either octreotate, octreotide, or Nal(3)-octreotide] PET is more sensitive and preferable to SRS <ref type="bibr" target="#b96">[95,</ref><ref type="bibr" target="#b109">107,</ref><ref type="bibr" target="#b115">[113]</ref><ref type="bibr" target="#b116">[114]</ref><ref type="bibr" target="#b117">[115]</ref><ref type="bibr" target="#b118">[116]</ref>.</s><s>C 11 -5-hydroxytryptophan PET and 64 Cu DOTATATE are promising techniques for lung NET, but experience is limited to single centers <ref type="bibr" target="#b119">[117,</ref><ref type="bibr" target="#b120">118]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>other diagnostic techniques</head><p><s>Other techniques are required to reach the definitive diagnosis and to perform the WHO classification and staging.</s><s>These include: bronchoscopy Bronchoscopy is indicated in all the central forms.</s><s>It also enables biopsy.</s><s>Flexible bronchoscopy is preferable; however, the clinician should be aware of the possibility of bleeding.</s><s>In patients at high risk for bleeding, rigid bronchoscopy may be preferred, both for obtaining biopsy specimens and also for performing ablation procedures <ref type="bibr" target="#b95">[94,</ref><ref type="bibr" target="#b97">96,</ref><ref type="bibr" target="#b121">119]</ref>.</s></p><p><s>There is currently limited evidence regarding the added value of new bronchoscopic techniques (echo-endoscopy, fluorescence bronchoscopy, and microbronchoscopy) to increase the sensitivity of detection of primary tumors, recurrence, or mediastinum lymph node staging and to determine endobronchial tumor margins before surgical resection <ref type="bibr" target="#b122">[120,</ref><ref type="bibr" target="#b123">121]</ref>.</s></p><p><s>For peripheral lesions, biopsy specimen may be obtained by either endoscopic transbronchial biopsy or more frequently a transthoracic CT-guided biopsy.</s><s>It should be emphasized that the small biopsies may make it difficult to differentiate between TC and AC <ref type="bibr" target="#b70">[69,</ref><ref type="bibr" target="#b95">94,</ref><ref type="bibr" target="#b97">96,</ref><ref type="bibr" target="#b121">119,</ref><ref type="bibr" target="#b122">120]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>functional respiratory tests</head><p><s>Functional respiratory tests should always be carried out to assess the surgical risk and to screen for bronchostenosis and to assess for the not infrequent association with chronic obstructive airways disease <ref type="bibr" target="#b124">[122]</ref>.</s><s>echocardiography Echocardiography should be carried out at diagnosis and in the course of follow-up to evaluate the presence and evolution of carcinoid heart disease <ref type="bibr" target="#b125">[123]</ref>.</s><s>In PC, left-as well as right-side valves should be screened <ref type="bibr" target="#b125">[123,</ref><ref type="bibr" target="#b126">124]</ref>.</s><s>Accurate echocardiographic evaluation should always be carried out before surgical procedures.</s></p><p><s>It should be remembered that the carcinoid syndrome may be diagnosed in pulmonary NET even in the absence of liver metastases and therefore carcinoid heart disease may be present, particularly on the left side.</s><s>Furthermore, the association with AC syndrome with bronchospasm may additionally impact on the heart function.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>cerebral CT or MRI</head><p><s>Cerebral metastases are a common event in poorly differentiated NETs, but are anecdotal in PC more often with higher grade AC.</s><s>Cerebral CT or MR is not routinely recommended, but should be carried out in the staging phase and during the follow-up when there is clinical suspicion or indication of disease.</s><s>For the same reasons, prophylactic cerebral radiotherapy, which is recommended in small cell carcinoma, is not justified in these tumors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>diagnosis: recommendations for the best practice</head><p><s>• Biochemical baseline tests should be limited to renal function, liver function, calcium, glucose, and plasma chromogranin A measurements (Level of Evidence 4, Grade of recommendation D).</s></p><p><s>• Paraneoplastic syndrome might occur in the setting of PC. Biochemical testing should be carried out in consideration of clinical symptoms and features including as appropriate 24-h urine 5-hydroxy-indole-acetic acid, ACTH, and GHRH (Level of Evidence 4, Grade of recommendation A).</s></p><p><s>• PC may be associated with MEN1 syndrome in &lt;5% of patients.</s><s>MEN1 is investigated by family history, clinical examination, and minimal laboratory screening (Level of Evidence 4, Grade of recommendation C).</s><s>If the familial history is suggestive of a MEN1 syndrome or a second MEN1 feature is present, screening for MEN1 gene mutation should be carried out (Level of Evidence 5, Grade of recommendation C).</s></p><p><s>• More than 40% of the cases may be incidentally detectable on a standard chest X-ray (Level of Evidence 3/4, Grade of recommendation C).</s></p><p><s>• The gold standard is contrast CT (Level of Evidence 3, Grade of recommendation B).</s><s>In patients in whom contrast is contraindicated, high-resolution CT may be used (Level of Evidence 4, Grade of recommendation C).</s></p><p><s>• Multiphase CT including arterial and portal phase or MRI with dynamic acquisition and diffusion-weighted sequences of the liver should be used for the detection of liver metastases (Level of Evidence 4, Grade of recommendation C).</s></p><p><s>• A CT chest and abdomen should be undertaken for preoperative staging (Level of Evidence 4, Grade of recommendation A, strong recommendation for good practice).</s></p><p><s>• Bronchoscopy may be required for the staging and assessment of central airway tumors preoperatively (Level of Evidence 4, Grade of recommendation A).</s></p><p><s>• Flexible bronchoscopy is preferable; however, in patients at high risk for bleeding, rigid bronchoscopy may be preferred for obtaining biopsy specimens (Level of Evidence 4, Grade of recommendation B).</s></p><p><s>• There is currently limited evidence regarding the added value of new bronchoscopic techniques to increase the sensitivity of detection of primary tumors or recurrence (Level of Evidence 4, Grade of recommendation D). • Whole-body SRS with thorax SPECT/CT may be useful to visualize nearly 80% of the primary tumors (Level of Evidence 4, Grade of recommendation B).</s></p><p><s>• SRS and SSTR PET imaging may have a higher grade of sensitivity for bone metastases (Level of evidence 4, Grade of recommendation D).</s></p><p><s>• Gallium-68-DOTA SSA PET is more sensitive and preferable to SRS if available (Level of Evidence 4, Grade of recommendation C).</s></p><p><s>• Most TCs have low or no uptake on FDG PET, whereas ACs may have higher uptake.</s><s>FDG PET is most useful for poorly differentiated forms (SCLC and LCLC) (Level of Evidence 4, Grade of recommendation C).</s></p><p><s>• Functional respiratory tests should always be carried out to assess the surgical risk and the association with chronic obstructive airways disease and to screen for bronchostenosis (Level of Evidence 4, Grade of Recommendation A).</s></p><p><s>• Echocardiography is always indicated in patients with carcinoid syndrome before surgery (Level of Evidence 4, Grade of recommendation B, strong recommendation for good practice).</s></p><p><s>In PC, left-as well as right-side valves should be screened (Level of Evidence 4, Grade of recommendation B).</s></p><p><s>surgery Surgical removal is the treatment of choice for PCs.</s><s>The aim is to remove the tumor and to preserve as much lung tissue as possible.</s><s>The surgical approach is dependent on the size, location, and tissue type.</s></p><p><s>surgery for localized disease complete anatomic resection and systematic nodal dissection.</s></p><p><s>For patients with peripheral lung tumors, the surgical extent of choice is complete anatomic resection (lobectomy and segmentectomy).</s><s>The extent of lymph node management should conform to the IASLC recommendations for the certainty factor in the designation of R0 resection; this involves a minimum of six nodes/stations, three of which should be mediastinal including the subcarinal station <ref type="bibr" target="#b127">[125]</ref>.</s></p><p><s>In patients with limited pulmonary function, the practice of a standard segment resection achieves better results than a broad wedge resection.</s><s>For peripheral AC, if only a limited sublobar resection is carried out, there may be increased probability of local recurrence postoperatively.</s><s>lung parenchymal-sparing surgery and systematic nodal dissection.</s><s>For patients with central airway tumors, lung parenchymal-sparing surgery is the favored surgical objective.</s><s>This is in view of the low malignant and recurrence potential (almost exclusively TC).</s><s>Where possible, bronchial sleeve resection (no lung tissue is removed) or a sleeve lobectomy should be carried out in preference to pneumonectomy (ideally with intraoperative frozen section of the resection margins) <ref type="bibr" target="#b128">[126]</ref>.</s><s>If necessary, patients should be referred to regional or national centers of excellence if such services are not available locally.</s><s>In the presence of distant pneumonitis and destroyed lung parenchyma, an initial local endobronchial resection to disobliterate the airway may be undertaken for drainage before re-assessment for lung parenchymal-sparing surgery <ref type="bibr" target="#b128">[126]</ref>.</s></p><p><s>Systemic nodal dissection should be carried out since lymph node metastases may be present in up to 25% of cases in TC and &gt;50% in AC <ref type="bibr" target="#b97">[96,</ref><ref type="bibr" target="#b129">127]</ref>.</s><s>local resection.</s><s>Endobronchial (e.g.</s><s>local diathermy resection and laser resection) or peripheral (e.g.</s><s>radiofrequency ablation, RF) local ablation techniques may be employed with palliative intent <ref type="bibr" target="#b128">[126]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>surgery for metastatic disease</head><p><s>There is little evidence to guide on surgery as part of multimodality management of patients with metastatic disease.</s><s>If pulmonary surgery is considered, then consensus would be to reserve surgery for patients with limited sites of disease with 'curative intent' where radical treatment is possible for all sites.</s><s>Such surgery is usually applied to TC and perhaps AC with low mitotic counts.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>liver resection</head><p><s>Surgical resection of liver metastases can be considered with curative intent, to aid symptom control or for debulking when &gt;90% of tumor can be removed.</s><s>Complete resection of liver metastases has increased 5-year overall survival rates to over 70% <ref type="bibr" target="#b130">[128]</ref>.</s><s>Thus, where possible, metastases should be resected.</s><s>The minimal requirements for curative intent are (i) resectable G1-G2 liver disease with acceptable morbidity and &lt;5% mortality; (ii) absence of right heart insufficiency; (iii) absence of unresectable lymph node and extra-abdominal metastases; and (iv) absence of diffuse or unresectable peritoneal carcinomatosis <ref type="bibr" target="#b131">[129]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>surgery for recurrent disease</head><p><s>In general, recurrent disease is uncommon, and surgery may be offered on the same premise of perioperative risk and stage selection as primary surgery.</s><s>Cases of regional recurrences have been noted up to and beyond 30 years from the original resection of the primary tumor <ref type="bibr" target="#b132">[130,</ref><ref type="bibr" target="#b133">131]</ref>.</s><s>Other studies have reported recurrences &gt;10 years from the initial resection <ref type="bibr" target="#b134">[132]</ref><ref type="bibr" target="#b135">[133]</ref><ref type="bibr" target="#b136">[134]</ref>.</s><s>Sometimes, it is possible to treat local recurrences with further surgery <ref type="bibr" target="#b136">[134]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>survey of surgical management</head><p><s>In June 2012, the European Society for Thoracic Surgery (ESTS, http://www.ests.org/default.aspx)</s><s>launched the Neuroendocrine Tumors of the Lung Working Group (NETs-WG) and included an electronic survey on PCs (E.</s><s>Lim, personal communication).</s><s>The questionnaire included 19 questions, organized in four sections:</s></p><p><s>• Preoperative patient assessment.</s></p><p><s>• Surgical approach to particular clinical NET scenarios.</s></p><p><s>• Follow-up organization.</s></p><p><s>• Treatment of tumor recurrences/metastases.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>special articles</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Annals of Oncology</head><p><s>One hundred and seventy-two institutions worldwide replied to this survey.</s><s>Concerning the surgical approach to well-differentiated lung NETs, an anatomic resection (either segmentectomy or lobectomy) was suggested for a peripheral PC by more than 88% of responders, whereas only 19 (11%) considered a wedge resection as an adequate surgical option.</s><s>In total, 164 (95%) responded that pneumonectomy should be avoided whenever feasible in case of centrally located PC, performing parenchymal-sparing resections, with preference for performing parenchymal-sparing resections; nevertheless, 8 (5%) still believed that pneumonectomy was the treatment of choice.</s><s>Lymphadenectomy, and in particular systematic hilar and mediastinal lymphadenectomy according to the ESTS recommendations for intraoperative lymph node assessment <ref type="bibr" target="#b114">[112]</ref>, was suggested by the majority of responders (64%); lymph node sampling was considered adequate by 34% of institutions, while four centers replied that they did not perform lymphadenectomy in any patient with PC.</s></p><p><s>In the case of a fit patient with resectable N2 PC, upfront surgery was suggested by more than half of responders, while induction chemotherapy was proposed by 71 centers (41%).</s></p><p><s>Furthermore, another unusual but sometimes described <ref type="bibr" target="#b137">[135]</ref><ref type="bibr" target="#b138">[136]</ref><ref type="bibr" target="#b139">[137]</ref> clinical scenario is represented by the multifocal PCs (bilateral synchronous/metachronous ones).</s><s>Currently, there is no consensus concerning their treatment, and a therapeutic strategy must be designed on a case-by-case basis.</s><s>Looking at the ESTS survey results, the lack of guidelines is confirmed by the fact that 36% of responders replied suggesting an anatomic resection, but the other answers were split between a non-anatomic resection and the resection of the larger lesion, only.</s></p><p><s>Finally, all but one of responders stated that surgery (if feasible) should be proposed in the case of recurrent TC, whereas other therapeutic options (biological therapy and conventional chemotherapy) were also suggested in the case of recurrent AC. local bronchoscopic therapy.</s><s>PCs without an extraluminal component can be treated at bronchoscopy resulting in an excellent long-term outcome with more tissue-sparing than immediate surgical resection.</s><s>For successful tumor eradication with initial bronchoscopic treatment, the assessment of intraluminal versus extraluminal growth may be of much more importance than histologic division between TC and AC <ref type="bibr" target="#b41">[42]</ref>.</s><s>To decrease the risk of local recurrence, cryotherapy is a safe and effective adjunct to endobronchial mechanical resection of TC and tends not to be associated with long-term complications such as bronchial stenosis <ref type="bibr" target="#b140">[138]</ref>.</s><s>In endoluminal PCs, laser bronchoscopy may be a curative option and offers many advantages as it is rapid, immediately effective and repeatable.</s><s>Laser bronchoscopy may also be used in association with other therapies (i.e.</s><s>radiotherapy) in cases of widespread intramural infiltration with an extraluminal component <ref type="bibr" target="#b141">[139]</ref>.</s><s>If the local treatment is not radical, surgical resection can follow bronchoscopic treatment.</s><s>This treatment strategy represents a minimally invasive and parenchyma sparing alternative, which may limit lobectomy to the cases of recurrence after endobronchial treatment.</s><s>Such local therapies need to be considered in the context of patient medical status, type of PC, and robust imaging including functional imaging to exclude nodal spread.</s></p><p><s>surgery: recommendations for the best practice • In the case of localized disease, the surgical techniques of choice are lobectomy or sleeve resection (Level of evidence 5, Grade of recommendation A).</s></p><p><s>• Complete anatomic resection and systematic nodal dissection are recommended as the resection extent of choice of patients with peripheral tumors (Level of Evidence 5, Grade of recommendation D).</s></p><p><s>• Lung parenchymal-sparing surgery should be preferred over pneumonectomy (Level of Evidence 5, Grade of recommendation C).</s></p><p><s>• Local resection should be reserved for patients who are considered unacceptably high risk for bronchopulmonary surgery (Level of Evidence 5, Grade of recommendation D).</s></p><p><s>• Endoluminal bronchoscopic therapy, more appropriately for TC, should be reserved for patients who are considered unacceptably high risk for bronchopulmonary surgery or occasionally as a possible bridge to surgery (Level of Evidence 5, Grade of recommendation D).</s></p><p><s>• Resection of liver metastases should be carried out whenever possible if curative intent is considered and in syndromic patients when &gt;90% of tumor burden can be removed.</s><s>The minimal requirements for curative intent include resectable TC and low-grade AC; &lt;5% mortality; absence of right heart insufficiency; absence of unresectable lymph node and extra-abdominal metastases; and absence of unresectable peritoneal carcinomatosis (Level of Evidence 4, Grade of recommendation C).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>medical therapy</head><p><s>Advanced AC is more aggressive than TC <ref type="bibr" target="#b129">[127,</ref><ref type="bibr" target="#b142">140]</ref>, and the medical management must incorporate multidisciplinary meeting review.</s><s>The goals are to control both hormone-related symptoms and tumor growth <ref type="bibr" target="#b80">[79,</ref><ref type="bibr" target="#b95">94,</ref><ref type="bibr" target="#b143">141]</ref>.</s><s>The prognostic heterogeneity and absence of curative therapeutic options at the metastatic stage make quality of life a core issue.</s><s>The key factors to take into account for medical management are the spontaneous slope without treatment, the metastatic spread of the primary tumor, SRS grade of uptake, and quality of control of hormone-related symptoms.</s><s>Based on the limited number of studies available in patients with primary PC, these recommendations also rely on data available for well-differentiated digestive NETs.</s><s>However, several significant parameters that differ from digestive NETs need to be stressed: a higher diversity of hormone-related symptoms, a bronchial-specific carcinoid syndrome that may exist even in patients free of liver metastases, low number of patients with distant metastases at diagnosis, higher prevalence of bone, cutaneous and brain metastases, and lower frequency of MEN1 syndrome.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>control of hormonal secretion</head><p><s>Symptoms related to hormone secretion are present in up to 30% of advanced PCs.</s><s>Carcinoid syndrome is the most frequent functioning syndrome in PC.</s><s>SSAs constitute the gold standard for symptomatic control.</s><s>A &gt;50% improvement in the frequency of flushing symptoms and diarrhea has been reported after SSA in GEP NETs <ref type="bibr" target="#b144">[142,</ref><ref type="bibr" target="#b145">143]</ref>.</s><s>A study specifically looking at the management of carcinoid syndrome in seven patients with AC showed complete control of symptoms with short-acting octreotide injections <ref type="bibr" target="#b146">[144]</ref>.</s><s>The presence of carcinoid heart disease should be carefully monitored.</s></p><p><s>Symptoms of Cushing syndrome are seen in 1-2% of patients with a PC and may be the initial reason for seeking medical attention.</s><s>Cushing syndrome could be treated with commonly available agents such as ketoconazole, metyrapone, etomidate, or mifepristone.</s><s>Ketoconazole, given at a daily dose of 600-800 mg, is the most popular and effective.</s><s>Metyrapone is also often used in this setting, and therapy starts at 1 g/day divided into four doses and increased to a maximum dose of 4.5 g/day.</s><s>For ectopic GHRH secretion and acromegaly, SSAs can be of value.</s><s>Some patients with ectopic ACTH syndrome might respond to SSA as well <ref type="bibr" target="#b80">[79]</ref>.</s><s>In the absence of hormonal control, other antitumor options need to be considered and these include: locoregional therapies [i.e.</s><s>liver palliative surgery, transarterial chemoembolization (TACE), and RF], combination of SSA with interferon (IFN) and PRRT in selected patients <ref type="bibr" target="#b80">[79,</ref><ref type="bibr" target="#b96">95]</ref>.</s><s>Prophylaxis against carcinoid crisis should be carried out before surgical or locoregional interventions using an adequate dosage of SSA.</s><s>For major procedures, a preoperative intravenous bolus of 100-200 µg, followed by a continuous infusion of 50 µg/h during the procedure, is recommended and the dose can be increased if required.</s><s>The infusion should continue for 24 h postoperatively before being slowly weaned over the next 48 h.</s><s>In such cases, it is likely that patients will require long-acting SSA <ref type="bibr" target="#b80">[79]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>adjuvant tumor control</head><p><s>Currently, there is no consensus on adjuvant therapy in PCs after complete resection.</s><s>Indeed, both prognostic studies and trials in the adjuvant setting are lacking.</s><s>Only patients with AC with positive lymph nodes, especially if there is a high proliferative index, should be considered for adjuvant therapy and discussed on an individual patient basis in the context of multidisciplinary tumor board meeting.</s><s>Clinical trials are needed in this setting.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>palliative tumor control</head><p><s>There are no prospective trials dedicated to PC that may guide treatment, and most literature consists of case series or studies that deal with a mixed population of primary NET patients.</s><s>Prognostic behavior and safety should be the first parameter to guide the therapeutic decision-making process.</s></p><p><s>In asymptomatic patients mainly with advanced TC or AC of low proliferative index as well as low tumor burden, a watch and see policy might be considered and explained to the patients on the basis of regular cross-sectional imaging initially 3-6 monthly.</s></p><p><s>SSA can induce stabilization in 30-70% of patients with welldifferentiated NETs as demonstrated in multiple prospective and retrospective studies that included PCs <ref type="bibr" target="#b147">[145]</ref><ref type="bibr" target="#b148">[146]</ref><ref type="bibr" target="#b149">[147]</ref>.</s><s>There are no dedicated trials, available for lung primary.</s><s>The randomized placebo controlled PROMID study of octreotide LAR 30 mg versus placebo in midgut NET (n = 85) demonstrated antitumor control with median time to progression significantly longer in the octreotide LAR 30 mg group than placebo, 14.3 months versus 6 months, respectively <ref type="bibr" target="#b150">[148]</ref>.</s><s>The phase III randomized placebo controlled (CLARINET) study in 204 patients with non-functional enteropancreatic NETs allocated to either lanreotide Autogel (120 mg/28 days) or placebo, and showed significantly prolonged progression-free survival over placebo (P = 0.0002) with 62% of lanreotide-treated patients versus 22% of placebo treated having not progressed at 96 weeks <ref type="bibr" target="#b151">[149]</ref>.</s></p><p><s>The most commonly used long-acting SSAs are octreotide LAR by deep i.m. injection and lanreotide Autogel given s.c., both administered every 28 days.</s><s>Due to their excellent safety profile, SSA should be considered as first-line systemic treatment of patients with advanced PCs of low proliferation index and positive SRS.</s><s>Caution should be exercised in patients with high tumor burden, high mitotic index or rapidly progressive tumor, and a first imaging carried out at 2-3 months.</s></p><p><s>In patients with slowly progressive tumors, multiple locoregional therapies aiming at reducing the tumor burden and targeting the bronchial primary and liver, bone, or bronchial metastases should be considered <ref type="bibr" target="#b80">[79,</ref><ref type="bibr" target="#b96">95]</ref>.</s><s>In contrast with digestive NETs, in whom mainly liver directed therapies are used, extra-liver metastases are frequently found in case of PCs and should also be considered as therapeutic targets.</s><s>Surgical resection can be considered with intent of resection of macroscopic metastases as outlined above mainly in slowly progressive TC and low proliferative AC, or in case of symptoms related to the primary location <ref type="bibr" target="#b131">[129,</ref><ref type="bibr" target="#b152">150,</ref><ref type="bibr" target="#b153">151]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>locoregional therapies</head><p><s>RF or cryoablation of the primary tumor are occasionally considered as an adjunct to surgery or whenever resection is not possible.</s><s>Liver but also bone or lung metastases constitute potential targets of RF ablation.</s><s>The size and anatomical locations constitute major predictors of efficacy.</s><s>Liver metastases derive the majority of their blood supply from the hepatic arteries; therefore, selective embolization with either bland particles (transarterial embolization, TAE) or cytotoxics such as doxorubicin (TACE) are found to be effective in improving symptoms and radiological response, particularly in GEP NETs.</s><s>Radiological response rates between 33 and 73% have been reported.</s><s>There is no evidence suggesting a beneficial response of chemoembolization over particle embolization alone.</s><s>There is emerging evidence of using radioactive microspheres such as Yttrium-90 in liver metastases.</s><s>The added value of combination of locoregional therapies as an adjunct to surgery or systemic therapy in case of progressive disease should be kept in mind <ref type="bibr" target="#b131">[129,</ref><ref type="bibr" target="#b152">150]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>peptide receptor radiotargeted therapy</head><p><s>Well-differentiated PCs frequently express subtype 2 of the SSTR family and this can be identified by Indium-111 SSA scintigraphy or Gallium-68 SSA PET scans, which constitute predictors of response.</s><s>PRRT may be used to treat metastases of TC and AC, with currently 90 Yttrium-DOTA octreotide and 177 Lutetium DOTA octreotide showing particular promise in selected patients with high uptake at SRS. Prospective and randomized trial results are warranted.</s><s>Early phase II studies of Yttrium-90 octreotide found the response rate to be as high as special articles Annals of Oncology 29% in seven PCs <ref type="bibr" target="#b154">[152]</ref>.</s><s>Although most studies are limited to single centers, a large retrospective study looking at 1109 metastatic NETs included 84 PCs, of which 28% showed a morphological response as estimated by RECIST criteria and 38.1% showed a clinical response with a mean survival of 40 months.</s><s>Grade 3-4 toxicity is reported in 10-33% of patients, mainly renal or hematological toxicities including irreversible renal toxicity (9.2%) <ref type="bibr" target="#b155">[153]</ref>.</s><s>Lutetium-177 DOTA octreotate (DOTATATE) is a combination of the beta-emitting Lutetium coupled with octreotate <ref type="bibr" target="#b156">[154]</ref>.</s><s>A study looking at foregut NETs with response to Lutetium-177 included nine PCs, of which five showed a partial response and just one had progressive disease <ref type="bibr" target="#b157">[155]</ref>.</s><s>The number of bone metastases and baseline glomerular filtration rate correlated with toxicity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>systemic chemotherapy</head><p><s>Systemic chemotherapy should be considered in patients with advanced unresectable progressive PC.</s><s>In general, results with chemotherapy have been largely disappointing and survival data have to be interpreted with caution due to the small numbers of patients, the mixed population of primary tumors, the absence of progression before the study enrollment, and the old standard criteria.</s><s>Overall response rate (ORR) below 30% has been described with 5-fluorouracil (5-FU), dacarbazine, and temozolomide (TMZ) alone or in combination, but also combinations of 5-FU with streptozotocin (STZ) or oxalipatin <ref type="bibr" target="#b158">[156]</ref><ref type="bibr" target="#b159">[157]</ref><ref type="bibr" target="#b160">[158]</ref>.</s><s>Their value in the management of advanced PCs remains unclear, but their level of G3-4 toxicity is expected above 10%.</s><s>TMZ is advocated as palliative treatment in PCs as it has been the most widely studied in the subgroup of lung NET and has an acceptable safety profile.</s><s>TMZ could also be considered in case of brain metastases <ref type="bibr" target="#b161">[159]</ref>.</s><s>Analysis of methylguanine DNA methyltransferase expression in NETs may help to select responders <ref type="bibr" target="#b162">[160]</ref>.</s><s>In lung NETs, a STZ-based regimen showed disappointing results with 7 of 7 patients progressing on STZ and 5-FU <ref type="bibr" target="#b163">[161]</ref>.</s><s>In a randomized trial analyzing 5-FU-STZ versus 5-FU-doxorubicin in symptomatic carcinoids including 22 PCs, 16% ORR was found with duration of 5 months and a survival advantage of the FU-STZ combination, suggesting that doxorubicin does not confer any benefit in these patients <ref type="bibr" target="#b158">[156]</ref>.</s><s>A retrospective analysis of 5-FU-STZ and cisplatin included 79 patients with progressive NET; of which, 8 were PCs.</s><s>The response rate in this study for non-pancreatic primary sites was 25%, with overall median TTP 9.1 months.</s><s>One PC patient had a partial response enabling surgery and resection of primary and nodal disease <ref type="bibr" target="#b164">[162]</ref>.</s><s>The combination of 5-FU and STZ plus or minus cisplatin (FCist) was recently re-examined in a randomized phase II trial of 85 consecutive NETs treated with this regimen and no added value of cisplatin was found <ref type="bibr" target="#b165">[163]</ref>.</s><s>A 20% response rate to cisplatin or carboplatin was reported in two studies specifically dedicated to well-differentiated PCs <ref type="bibr" target="#b163">[161,</ref><ref type="bibr" target="#b166">164]</ref>.</s><s>Due to its significant rate of toxicity, cisplatin should only be considered in patients with more aggressive, advanced PCs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>mtor inhibitors</head><p><s>Everolimus may be a therapeutic option after failure of other treatments in TC and AC.</s><s>Mammalian target of Rapamycin (mtor) has been identified as a kinase activated in the PI3K signaling pathway of lung NETs <ref type="bibr" target="#b167">[165]</ref>.</s><s>Recently, mutations of PI3CA were reported in TC and AC.</s><s>The randomized phase III RADIANT 2 trial assessed everolimus 10 mg + octreotide LAR versus placebo + octreotide LAR in 429 patients in non-pancreatic functioning (carcinoid syndrome) NETs.</s><s>The study demonstrated a clinically significant 5.1 month increase in median progression-free survival <ref type="bibr" target="#b168">[166]</ref>.</s><s>Within this RADIANT 2 trial, 44 primaries were of bronchial origin <ref type="bibr" target="#b169">[167]</ref>.</s><s>The RAMSETE study analyzed the antitumor benefit of everolimus in 19 foregut-derived NETs with RECIST progression over a year.</s><s>A progression-free survival of 189 days was reported <ref type="bibr" target="#b170">[168]</ref>.</s><s>The LUNA study is a three arm phase II trial assessing everolimus alone versus pasireotide (a pan-SSTR analog) versus combination and started recruiting in 2013 (LUNA study, see www.</s><s>clinical trials.gov/ct2/show/NCT01563354).</s><s>The randomized phase III RADIANT 4 trial, which assessed everolimus 10 mg versus placebo in 279 patients in non-functioning NETs including lung PCs, has been closed for enrollment and the results are expected in 2015.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>antiangiogenesis agents</head><p><s>The place of antiangiogenic agents in PC remains uncertain.</s><s>Sunitinib is an orally administered kinase inhibitor small molecule with activity against a number of tyrosine kinase inhibitors including VEGFR-1, -2, -3, platelet-derived growth factor receptor (PDGFR)-a, and -b <ref type="bibr" target="#b171">[169]</ref>.</s><s>A phase II study evaluated the activity of sunitinib in 109 NE patients including 41 with carcinoids; of whom, 14 were foregut including PC.</s><s>In the carcinoid patients, ORR was 2.4%, with stable disease in 83%, with a TTP of 10.2 months and 1-year survival rate of 83.4 <ref type="bibr" target="#b172">[170]</ref>.</s><s>The PAZONET study of pazopanib as a sequencing treatment in progressive metastatic NET showed a clinical benefit in 85% of patients treated with pazopanib, including patients with lung carcinoids <ref type="bibr" target="#b173">[171]</ref>.</s><s>Bevacizumab is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody and in a phase II study patients were randomized to either bevacuzimab or pegylated IFN, and 21 of 22 patients demonstrated a partial response in the bevacizumab group where 4 patients were PCs <ref type="bibr" target="#b174">[172]</ref>.</s><s>One phase II study analyzed the antitumor efficacy of sorafenib plus bevacizumab combination in 44 NETs, including 19 foregut NETs.</s><s>A 10% ORR was reported in digestive NETs <ref type="bibr" target="#b175">[173]</ref>.</s><s>More studies looking at antiangiogenic activity in PC are required.</s><s>Promising results have been published with the combination of bevacizumab and chemotherapy <ref type="bibr" target="#b176">[174]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>erlotinib and EGFR inhibitors</head><p><s>The epidermal growth factor (EGF) pathway has been found to be expressed in PC, but no mutation has been reported to date.</s><s>In vitro and in vivo studies using the EGF receptor inhibitor erlotinib suggested a potential role and currently phase II studies are ongoing (www.clinicaltrials.gov.</s><s>NCT0084 3531 RAD001 and erlotinib in patients with NETs 2012; available from: http://www.clinicaltrials.gov/ct2/results?termZNCT00843531).</s><s>Other pathways being investigated are fibroblast growth factor and MET pathways, with a range of new molecules being developed for the VEGF and PDGF pathways <ref type="bibr" target="#b177">[175]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>follow-up</head><p><s>After primary surgery, patients with TC and AC should be followed initially at least yearly.</s><s>However, the follow-up needs to be long term even if less frequent to detect surgically manageable recurrences.</s><s>Liver, mediastinum and abdomen lymph nodes, lung, cutaneous, and/or bone metastases are routinely evaluated by appropriate means.</s><s>In case of high tumor burden or specific symptoms, brain metastases should be considered.</s><s>Conventional imaging is carried out at 3 and 6 months and then every 12 months in TC together with chromogranin A measurements for the first 2 years.</s><s>Then annual chest X-ray and biochemistry profile and a CT every 3 years long-term are recommended.</s><s>The frequency may be more frequent in R1 or node-positive patients.</s><s>SRS should be carried out at 12 months and then only on suspicion of recurrence for TC.</s><s>For AC, closer monitoring is recommended.</s><s>CT imaging should be carried out 3 months postsurgery and then 6 monthly for 5 years with biochemical markers.</s><s>SRS imaging is carried out at 1 year and then on suspicion of recurrence.</s><s>After 5 years, annual CT should be carried out.</s><s>In selected patients with high proliferative index, FDG PET may be more informative and replace SRS imaging.</s></p><p><s>At the time of a therapeutic intervention, patients should be routinely monitored every 3 months.</s><s>Fiberoptic bronchoscopy is carried out for any symptoms suggestive of local progression and on a routine basis every 5-10 years for TC or 1-3 years in case of AC.</s><s>The type of surgery, the R status, and the size of the primary will also be taken into account to define the most appropriate interval <ref type="bibr" target="#b80">[79,</ref><ref type="bibr" target="#b96">95,</ref><ref type="bibr" target="#b178">176]</ref>.</s><s>medical therapy: recommendations for the best practice • SSAs are the first-line treatment of carcinoid syndrome and acromegaly (Level of Evidence 3; Grade of recommendation B).</s></p><p><s>• In patients with Cushing syndrome, control of cortisol secretion is needed (Level of Evidence 3; Grade of recommendation B).</s></p><p><s>• Bilateral adrenalectomy is a therapeutic option for refractory Cushing syndrome (Level of Evidence 5; Grade of recommendation D).</s></p><p><s>• SSA may be considered as first-line systemic antiproliferative treatment of patients with advanced unresectable PC of good prognosis particularly TC and AC with low proliferative index, and slowly progressive provided that SRI is positive (Level of Evidence 3; Grade of recommendation B).</s></p><p><s>• Locoregional options including surgery (for primary and metastases), TAE, and RF should always be considered for slow progressive PC (Level of Evidence 4; Grade of recommendation C).</s></p><p><s>• Cytotoxic treatment has been the standard for aggressive metastatic PCs, although the available chemotherapy regimens demonstrate a limited effect (Level of Evidence 3; Grade of recommendation B).</s></p><p><s>• TMZ alone has demonstrated clinical benefit (Level of Evidence 3; Grade of recommendation C).</s><s>A combination of cisplatinum and etoposide is mainly used in high proliferating PC (Level of Evidence 3; Grade of recommendation B).</s></p><p><s>• PRRT is an option in patients with tumors that demonstrate strong expression of SSTRs (Level of Evidence 3; Grade of recommendation C, strong recommendation for good practice).</s></p><p><s>• There is evidence of preliminary efficacy for everolimus in the treatment of progressive PC.</s><s>The ongoing randomized phase III LUNA study will determine future management (Level of Evidence 4; Grade of recommendation D).</s></p><p><s>• There is no consensus on adjuvant therapy in PCs after complete resection.</s><s>There might be consideration in patient with AC of high proliferative index (Level of Evidence 4; Grade of recommendation D).</s></p><p><s>• After primary surgery, patients with TC and AC should be followed long term (Level of Evidence 4; Grade of recommendation B).</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>•</head><label></label><figDesc><div><p><s>Pathology is the gold standard in the assessment of any pulmonary NET diagnosis.</s><s>Problem cases may benefit from review by expert pathologists (Level of Evidence 3; Grade of recommendation B).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>•</head><label></label><figDesc><div><p><s>A watch and see policy may be considered in a subgroup of asymptomatic patients mainly with TC or AC of low proliferative index (Level of Evidence 5; Grade of recommendation D).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>disclosure MEC: advisory board and research funding from Novartis, Ipsen, and Lexicon.</s><s>EB: advisory board and consultancy from Novartis, Ipsen, HRA Pharma, Roche, Pfizer, and AAA.</s><s>PF: advisory boards and consultancy for Novartis, Ipsen, Lexicon, and Italfarmaco.</s><s>EL: personal fees from Abbott Molecular, Glaxo Smith Kline, Pfizer, Norvatis, Covidien, Roche, Lily Oncology, Boehringer Ingelheim, Medela, grants, and personal fees from ScreenCell.</s><s>All remaining authors have declared no conflicts of interest.</s><s>references special articles Annals of Oncology</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>67 labeling index assessment in NE lung tumors: (i) Ki-67 is useful in biopsy for distinguishing TC and AC from SCLC cytology (Level of Evidence 4; Grade of recommendation C); (ii) Ki-67 does not reliably distinguish TC from AC in any material (Level of Evidence 4; Grade of recommendation C); (iii) Ki-67 has been shown to predict prognosis of TC and AC (Level of Evidence 4; Grade of recommendation C); and (iv) the optimal procedure for performing Ki-67 ICH and the criteria for performing the relevant labeling index (digital image analysis, manual counting, eyeball evaluation, hotspot areas versus randomly selected field versus entire tumor area, and number of cells) remains to be settled (Level of Evidence 4/5; Grade of recommendation C).</s></p></div></figDesc><table /><note><p><s>• A few NE immunomarkers (chromogranin A, synaptophysin, and/or CD56/NCAM) may be used to confirm NE nature of tumors especially in biopsy/cytology specimens or surgical specimens, if needed.In case of metastatic PC presentation, positive TTF1 staining is suggestive of a lung or thyroid origin (Level of Evidence 3; Grade of recommendation C).• NE cell hyperplasia, tumorlets, DIPNECH, and multiple tumors should be carefully documented and most often pertain to PCs.DIPNECH is a pre-invasive lesion able to progress to TC or AC.Histological evaluation may provide information to decide if multiple PCs are intrapulmonary seeding or multiple primaries, as an association with NE cell hyperplasia, tumorlets, or DIPNECH favors multiple NETs (Level of Evidence 4; Grade of recommendation C).•No proof has been provided that different histological tumor cell features may have clinical significance, although they may seriously impact differential diagnosis.Cell atypia or pleomorphism is not useful to classify PCs (Level of Evidence 4; Grade of recommendation C).•No molecular tests should currently be routinely carried out in PCs, unless specifically required by study protocols (Level of Evidence 4; Grade of recommendation C).diagnosisPCs are traditionally subdivided into central and peripheral on the basis of their origin in respect of the bronchial tree; however, they can occur throughout the lung parenchyma.</s><s>Respiratory symptoms are generally present only in central forms, while peripheral forms are generally discovered as an incidental finding in the course of radiological procedure carried out for other reasons.</s><s>The most frequent respiratory symptoms are recurrent chest infections, cough, hemoptysis, chest pain, dyspnea, and wheezing.</s><s>In rare cases, hormonal hypersecretion reveals the underlying tumor.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>Algorithm for diagnosis of pulmonary neuroendocrine tumor.</s></p></div></figDesc><table><row><cell cols="2">Clinical suspicion of pulmonary neuroendocrine tumor (Typical or Atypical Carcinoid)</cell><cell>Evaluate possible MEN1 association (include: ionized serum calcium, PTH, consider MEN1 gene mutational analysis)</cell></row><row><cell></cell><cell></cell><cell>Assessment of biochemical secretion</cell></row><row><cell></cell><cell></cell><cell>depending on clinical signs and history:</cell></row><row><cell></cell><cell></cell><cell>24h urine 5HIAA</cell></row><row><cell>Spine MRI if symproms or suspicion of metastases</cell><cell>Multiphasic contrast CT chest &amp; abdomen</cell><cell>serum cortisol and ACTH GHRH, IGF1</cell></row><row><cell></cell><cell></cell><cell>If considering surgery perform:</cell></row><row><cell></cell><cell></cell><cell>Echocardiography</cell></row><row><cell></cell><cell></cell><cell>Respiratory Function testing</cell></row><row><cell>If positive cytology or histopathology: OctreoScan TM or Ga68-</cell><cell>Bronchoschopy (EBUS in selected cases)</cell><cell></cell></row><row><cell>DOTA-Octreotate PET.</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Histopathology: Evaluation of Mitotic</cell></row><row><cell></cell><cell></cell><cell>count and/or necrosis, include Ki67</cell></row><row><cell>Consider FDG-PET in AC or high grade histopathology</cell><cell>Transthoracic and/or transbronchial biopsy.</cell><cell>proliferation index. Cytopathology: may not differentiate TC</cell></row><row><cell></cell><cell>Metastatic disease: biopsy</cell><cell>from AC</cell></row><row><cell></cell><cell>most accessible site</cell><cell></cell></row><row><cell>Figure 1.</cell><cell></cell><cell></cell></row></table><note><p><s>Volume 26 | No. 8 | August 2015 doi:10.1093/annonc/mdv041</s><s>|  Annals of Oncology special articles addition to multiple nodules due to the tumorlets and carcinoid tumors.</s></p></note></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Klimstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Coppola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pancreas</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="707" to="712" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">W</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Brambilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Muller-Hermelink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pleura, Thymus and Heart</title>
		<imprint>
			<date type="published" when="2004">2004</date>
			<publisher>IARC Press</publisher>
		</imprint>
	</monogr>
	<note>Tumours of the Lung</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Neuroendocrine neoplasms of the lung</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Cerilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Ritter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wick</forename><surname>Mrl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="S65" to="S96" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Neuroendocrine carcinomas of the lung: a critical analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Coppola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Wick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="206" to="221" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Neuroendocrine neoplasia. Current concepts</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Wick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="331" to="335" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Revised classification of neuroendocrine tumors of the lung, pancreas and gut</title>
		<author>
			<persName><forename type="first">C</forename><surname>Capella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">U</forename><surname>Heitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hofler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Solcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Klöppel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Digestion</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="11" to="23" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muzitansky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Mark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="545" to="553" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Skov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krasnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lantuejoul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Skov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Brambilla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1410" to="1415" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province</title>
		<author>
			<persName><forename type="first">M</forename><surname>Alsina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marcos-Gragera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Capdevila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="e49" to="e54" />
			<date type="published" when="1994">1994-2004. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>De Jong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schaapveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Blaauwgeers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Groen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Pulmonary tumors in the Netherlands: focus on temporal trends in histology and stage and on rare tumors</title>
				<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1096" to="1102" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature</title>
		<author>
			<persName><forename type="first">G</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Krelbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yellin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1647" to="1651" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Bronchopulmonary carcinoids in Iceland 1955-1984. A retrospective clinical and histopathologic study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Hallgrimsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jonsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Johannsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="275" to="278" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumor epidemiology: contrasting Norway and North America</title>
		<author>
			<persName><forename type="first">O</forename><surname>Hauso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Gustafsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="2655" to="2664" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hemminki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="2204" to="2210" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97</title>
		<author>
			<persName><forename type="first">F</forename><surname>Levi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Te</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Randimbison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rindi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">La</forename><surname>Vecchia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="952" to="955" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">A 5-decade analysis of 13,715 carcinoid tumors</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Lye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="934" to="959" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Carcinoid lung tumors-incidence, treatment and outcomes: a population-based study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Naalsund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Rostad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Strom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Strom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Lund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Strand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="565" to="569" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Koniaris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Snell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Surg</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1022" to="1030" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Quaedvlieg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Lamers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Janssen-Heijen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Taal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1295" to="1300" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark</title>
		<author>
			<persName><forename type="first">H</forename><surname>Skuladottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Hirsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Olsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="127" to="135" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">One hundred years after &apos;carcinoid&apos;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Phan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3063" to="3072" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Familial carcinoid tumors and subsequent cancers: a nationwide epidemiologic study from Sweden</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hemminki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="444" to="448" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Survival from rare cancer in adults: a population-based study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Gatta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ciccolallo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kunkler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="132" to="140" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Lung cancer</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Devesa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="191" to="202" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening</title>
		<author>
			<persName><forename type="first">D</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vazquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Flieder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="193" to="199" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and two-year repeat study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Pelosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sonzogni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Veronesi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="202" to="214" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Bronchopulmonary neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Gustafsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Malfertheiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="5" to="21" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Baumgarten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Isacson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mckeen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="2476" to="2483" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties</title>
		<author>
			<persName><forename type="first">J</forename><surname>Soga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yakuwa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="211" to="219" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: the NET MANAGEMENT study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Faggiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Grimaldi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Endocrinol Invest</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="817" to="823" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="867" to="873" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Bronchial carcinoid tumors: surgical management and long-term outcome</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Filosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Donati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="303" to="309" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Metastatic carcinoid tumors: a clinical review</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Zuetenhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Taal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="123" to="131" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Broaddus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Herzog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Hicks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1200" to="1203" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children&apos;s hospital</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Dishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kuruvilla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="1079" to="1103" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Primary epithelial lung malignancies in the pediatric population</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Lal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shalkow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="683" to="686" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Bronchial carcinoid tumors in children: surgical treatment and outcome in a single institution</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rizzardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Marulli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Calabrese</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pediatr Surg</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="228" to="231" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Primary lung tumors in children and adolescents: a 90-year experience</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Grabowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Kozakewich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr Surg</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1090" to="1095" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumors of the lung: an update</title>
		<author>
			<persName><forename type="first">N</forename><surname>Rekhtman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1628" to="1638" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">International Multidisciplinary Classification of lung adenocarcinoma</title>
		<author>
			<persName><forename type="first">W</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Brambilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Noguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="244" to="285" />
			<date type="published" when="2011">2011</date>
			<publisher>American Thoracic Society/European Respiratory Society</publisher>
		</imprint>
	</monogr>
	<note>International association for the study of lung cancer</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Pulmonary atypical carcinoid: predictors of survival in 106 cases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Beasley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Thunnissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Brambilla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1255" to="1265" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Brokx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Risse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Paul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="973" to="978" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Evaluation of primary pulmonary carcinoid tumors using FDG PET</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Erasmus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Mcadams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Patz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jr</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="1369" to="1373" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Bronchial carcinoids. A review of 22 cases</title>
		<author>
			<persName><forename type="first">M</forename><surname>Froudarakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fournel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Burgard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncology</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="153" to="158" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Carcinoid tumors of the lung: immuno-and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kayser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kayser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Rahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Bovin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Gabius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="99" to="106" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Tumorlets in familial history of bronchopulmonary carcinoid</title>
		<author>
			<persName><forename type="first">U</forename><surname>De Giorgi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fanini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Amadori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1613" to="1614" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Familial pulmonary carcinoid tumors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Tazelaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Wentzlaff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="2104" to="2109" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Genetics of neuroendocrine and carcinoid tumors</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Leotlela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Holtgreve-Grez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Thakker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="437" to="450" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Melanocytic bronchopulmonary carcinoid tumor in a patient with multiple endocrine neoplasia syndrome type 1: a case report with emphasis on intraoperative cytological findings</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Matsuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nobrega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quezado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Schrump</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Filie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Cytopathol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="669" to="674" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1</title>
		<author>
			<persName><forename type="first">N</forename><surname>Sachithanandan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Harle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Burgess</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="509" to="515" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Tumorlets, multicentric carcinoids, lymphnodal metastases, and long-term behavior in bronchial carcinoids</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Daddi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Urbani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="383" to="387" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rugge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Clemente</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="149" to="154" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Giroux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chansky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1213" to="1223" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sarkaria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pietanza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Surg</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="1156" to="1162" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title level="m" type="main">Histological Typing of Lung and Pleural Tumors</title>
		<author>
			<persName><forename type="first">W</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Colby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Corrin</forename><forename type="middle">B</forename></persName>
		</author>
		<imprint>
			<date type="published" when="1999">1999</date>
			<publisher>Springer-Verlag</publisher>
			<pubPlace>Berlin, Heidelberg, New York</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Grading the neuroendocrine tumors of the lung: an evidence-based proposal</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rindi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Klersy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Inzani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The neuroendocrine lung</title>
		<author>
			<persName><forename type="first">C</forename><surname>Axiotis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Endocrine Pathology</title>
				<editor>
			<persName><forename type="first">Li</forename><surname>Volsi</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">V</forename></persName>
		</editor>
		<editor>
			<persName><forename type="first">Asa</forename><forename type="middle">S</forename></persName>
		</editor>
		<meeting><address><addrLine>Edinburgh, New York: Churchill Livingstone</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2002">2002</date>
			<biblScope unit="page" from="261" to="296" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Revised classification of neuroendocrine tumors of the lung, pancreas and gut</title>
		<author>
			<persName><forename type="first">C</forename><surname>Capella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">U</forename><surname>Heitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hofler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Solcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Klöppel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">425</biblScope>
			<biblScope unit="page" from="547" to="560" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<title level="m" type="main">Histological Typing of Endocrine Tumors</title>
		<author>
			<persName><forename type="first">E</forename><surname>Solcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Klöppel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sobin</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
			<publisher>Springer</publisher>
			<pubPlace>Heidelberg</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Multi-directional differentiation of Ascl1-defined progenitors in lung development and injury repair</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Linnoila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Cell Mol Biol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="768" to="775" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Functional facets of the pulmonary neuroendocrine system</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Linnoila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="425" to="444" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">The molecular basis of lung morphogenesis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Warburton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tefft</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mech Dev</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="55" to="81" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Comparative epidemiology of carcinoid and oat-cell tumors of the lung</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Godwin</surname></persName>
		</author>
		<author>
			<persName><surname>Ii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1671" to="1673" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">WHO Classification of Tumors of the Digestive System</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bosman</surname></persName>
			<affiliation>
				<orgName type="collaboration">IARC</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Carneiro</surname></persName>
			<affiliation>
				<orgName type="collaboration">IARC</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hruban</surname></persName>
			<affiliation>
				<orgName type="collaboration">IARC</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lyon: International Agency for Research on Cancer</title>
		<imprint>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<title/>
		<idno type="DOI">10.1093/annonc/mdv041|</idno>
		<imprint>
			<date type="published" when="2015-08">August 2015</date>
			<biblScope unit="volume">26</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Reproducibility of neuroendocrine lung tumor classification</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Gal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Colby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="272" to="279" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tsuta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kalhor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Wistuba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Moran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="252" to="259" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Clinical Lung Cancer Genome Project (CLCGP</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">A genomics-based classification of human lung tumors</title>
	</analytic>
	<monogr>
		<title level="j">Network Genomic Medicine (NGM)</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="209" to="153" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Sci Transl Med</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zahel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Krysa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Herpel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">460</biblScope>
			<biblScope unit="page" from="299" to="308" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients</title>
		<author>
			<persName><forename type="first">G</forename><surname>Pelosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rosai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="179" to="187" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Skov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Holm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Erreboe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Skov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mellemgaard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="453" to="459" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Walts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Marchevsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Pathol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1258" to="1264" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score</title>
		<author>
			<persName><forename type="first">F</forename><surname>Grimaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Muser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Beltrami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Endocrinol (Lausanne)</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<title level="m" type="main">TNM Classification of Malignant Tumours</title>
		<author>
			<persName><forename type="first">L</forename><surname>Sobin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gospodarowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wittekind</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
			<publisher>Wiley-Blackwell</publisher>
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rindi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kloppel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Alhman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">449</biblScope>
			<biblScope unit="page" from="395" to="401" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hedvat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Klimstra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1761" to="1770" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study</title>
		<author>
			<persName><forename type="first">V</forename><surname>Costes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Marty-Ane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Picot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="740" to="745" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tsuta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kalhor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Raso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Wistuba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Moran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="578" to="585" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids</title>
		<author>
			<persName><forename type="first">A</forename><surname>Warth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fisseler-Eckhoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">462</biblScope>
			<biblScope unit="page" from="507" to="513" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Choi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pancreas</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="784" to="798" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Muller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="653" to="658" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Morphology and antigen expression profile of pulmonary neuroendocrine cells in reactive proliferations and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Gosney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Dodson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Foster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="751" to="762" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cavazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Graziano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Papotti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="page" from="341" to="342" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Diffuse idiopathic pulmonary neurendocrine cell hyperplasia: a systematic overview</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Nassar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Jaroszewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Helmers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="8" to="16" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">What is DIPNECH?</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vummidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Benditt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Godwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pipavath</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Imaging</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="647" to="649" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Spectrum of pulmonary neuroendocrine cell proliferation: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Koo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Baliff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Torigian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">195</biblScope>
			<biblScope unit="page" from="661" to="668" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Riniker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Anlauf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="420" to="425" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Konukiewitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Perren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Klöppel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">459</biblScope>
			<biblScope unit="page" from="147" to="154" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Neuroendocrine differentiation and prognosis in breast adenocarcinoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Miremadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Pinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="215" to="222" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Clinical significance of neuroendocrine carcinoma of the breast</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sapino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Papotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Righi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S115" to="S117" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Somatostatin receptor tissue distribution in lung neuroendocrine tumors: a clinicopathologic and immunohistochemical study of 218 &apos;clinically aggressive&apos; cases</title>
		<author>
			<persName><forename type="first">L</forename><surname>Righi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Volante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Tavaglione</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="548" to="555" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Biological characterization of neuroendocrine tumors: the role of neuroendocrine markers</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Faggiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mansueto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Endocrinol Invest</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="277" to="286" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bajetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Martinetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="858" to="865" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gigliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ducreux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="1102" to="1107" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Goldstraw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Nicholson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1194" to="1201" />
			<date type="published" when="2007">2007. 2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName><forename type="first">K</forename><surname>Öberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hellman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Papotti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">S7</biblScope>
			<biblScope unit="page" from="120" to="123" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Surgical treatment of neuroendocrine tumors of the lung</title>
		<author>
			<persName><forename type="first">N</forename><surname>Daddi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Urbani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="813" to="817" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Paraneoplastic syndromes secondary to neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">G</forename><surname>Kaltsas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Androulakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>De Herder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Grossman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="R173" to="R193" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Thakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Newey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Walls</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="2990" to="3011" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Guidelines for diagnosis and therapy of MEN type 1 and type 2</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Brandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Gagel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Angeli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="5658" to="5671" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Jeung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gasser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gangi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiographics</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="351" to="365" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">CT features of peripheral pulmonary carcinoid tumors</title>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">C</forename><surname>Meisinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Butnor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gentchos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Leavitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">197</biblScope>
			<biblScope unit="page" from="1073" to="1080" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumors: a long-term single institution experience</title>
		<author>
			<persName><forename type="first">L</forename><surname>Schrevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vansteenkiste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Deneffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="39" to="45" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Members of the Spanish Multicenter Study of Neuroendocrine Tumors of the Lung by the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Typical and atypical carcinoid: analysis of the experience of the Spanish multicenter study of neuroendocrine tumors of the lung</title>
		<author>
			<persName><forename type="first">M</forename><surname>García-Yuste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Matilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cueto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardio Thorac Surg</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="192" to="197" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bhosale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Radiol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="400" to="407" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<monogr>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Vullierme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kaltsas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Plöckinger</surname></persName>
		</author>
		<title level="m">Mallorca Consensus Conference participants</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations</title>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="167" to="183" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Leboulleux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dromain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Vataire</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page">3021</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nanni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zompatori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">68</biblScope>
			<biblScope unit="page" from="722" to="727" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Octreoscan in patients with bronchial carcinoid tumors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Granberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Janson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Endocrinol (Oxf )</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="793" to="799" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Performance of (18) fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (10%) well-differentiated endocrine carcinoma staging</title>
		<author>
			<persName><forename type="first">R</forename><surname>Abgral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leboulleux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Déandreis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="665" to="671" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Tumors in the tracheobronchial tree: CT and FDG PET features</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Goo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiographics</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="55" to="71" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Daniels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aubry</forename><forename type="middle">Mc</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Jett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="255" to="260" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumors</title>
		<author>
			<persName><forename type="first">H</forename><surname>Pattenden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Beddow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dusmet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl; abstr 7544</note>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">68 Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Castellucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rubello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucl Med Commun</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="281" to="286" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Decristoforo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kendler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="508" to="518" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">A comparison of 68 Ga-DOTATATE and 18 F-FDG PET/CT in pulmonary neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kayani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Conry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Groves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1927" to="1932" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">The role of 68 Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111 In-DTPA-octreotide scintigraphy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Srirajaskanthan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kayani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Quigley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="875" to="882" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Clinical PET of neuroendocrine tumors using 64 Cu-DOTATATE: first-in-humans study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pfeifer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Knigge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mortensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1207" to="1215" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography</title>
		<author>
			<persName><forename type="first">H</forename><surname>Orlefors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Garske</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="3392" to="3400" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Diagnosis of lung cancer: the guidelines</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Rivera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Detterbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Mehta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="129S" to="136S" />
			<date type="published" when="2003">2003</date>
			<publisher>American College of Chest Physicians</publisher>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Diagnosis of peripheral pulmonary carcinoid tumor using endobronchial ultrasound</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Steinfort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Irving</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="146" to="148" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Clinical application of direct bronchial ultrasound to visualize and determine endobronchial tumor margins for surgical resection</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Sarraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Belcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Surg</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="1339" to="1341" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Pulmonary assessment for general thoracic surgery</title>
		<author>
			<persName><forename type="first">F</forename><surname>Banki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surg Clin North Am</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="969" to="984" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Consensus guidelines for the standards of care in neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">U</forename><surname>Plockinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gustafsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Szpak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Davar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">echocardiography. Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="190" to="193" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">ACC/AHA/ASE 2003 guidelines uptake for the clinical application of echocardiograph: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Cheitlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Aurigemma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Echocardiogr</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1091" to="1110" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<monogr>
		<title level="m" type="main">International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology</title>
		<author>
			<persName><forename type="first">P</forename><surname>Goldstraw</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2009">2009</date>
			<publisher>Editorial Rx Press</publisher>
			<pubPlace>Florida, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Management of carcinoid tumors</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Detterbeck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Surg</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="998" to="1005" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Yap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Stavola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Nicholson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Goldstraw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="969" to="972" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Long-term survival after surgical management of neuroendocrine hepatic metastases</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Glazer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Tseng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Al-Refaie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">HPB (Oxford)</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="427" to="433" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Couvelard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="157" to="176" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Carcinoid tumors of the lung</title>
		<author>
			<persName><forename type="first">N</forename><surname>Okike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Bernatz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Woolner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Surg</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="270" to="277" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Diagnosis and treatment of bronchial carcinoid tumors: clinical and pathological review of 120 operated patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Vadasz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Palffy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Egervary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Schaff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="8" to="11" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Carcinoid tumours of the bronchus: a 33 year experience</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hurt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bates</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="617" to="623" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Low grade neuroendocrine tumors of the lung (bronchial carcinoids)-25 years&apos; experience</title>
		<author>
			<persName><forename type="first">F</forename><surname>Francioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Rendina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Venuta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="472" to="476" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour</title>
		<author>
			<persName><forename type="first">G</forename><surname>Stamatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Freitag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Greschuchna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="527" to="532" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>Report on 227 cases. discussion 533</note>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Synchronous bilateral typical pulmonary carcinoid tumors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Beshay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Schmid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="251" to="253" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Synchronous bilateral lung carcinoid tumors: a rare entity</title>
		<author>
			<persName><forename type="first">L</forename><surname>Spaggiari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Veronesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gasparri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pelosi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="334" to="337" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Metachronous bronchial carcinoid tumor</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rizzardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Marulli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bortolotti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="394" to="396" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumor</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bertoletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Elleuch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kaczmarek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jean-François</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Vergnon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1405" to="1411" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Nd:YAG laser bronchoscopy. A five-year experience with 1,396 applications in 1,000 patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cavaliere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Foccoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Farina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="15" to="21" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Bronchopulmonary carcinoid tumors: long-term outcomes after resection</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kennedy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Surg</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="339" to="343" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Pulmonary euroendocrine/carcinoid tumors: a review article</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Bertino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Confer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Colonna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Otterson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="4434" to="4441" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ferone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kaltsas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="209" to="213" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Gustafsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="169" to="188" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Filosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ruffini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oliaro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="913" to="917" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">T</forename><surname>Aparicio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ducreux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1014" to="1019" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">The antitumoral effect of the longacting somatostatin analog lanreotide in neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ducreux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ruszniewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Chayvialle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="3276" to="3281" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group</title>
		<author>
			<persName><forename type="first">S</forename><surname>Faiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">F</forename><surname>Pape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Böhmig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2689" to="2696" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schade-Brittinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="4656" to="4663" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<monogr>
		<title level="m" type="main">A randomized, double-blind, placebocontrolled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Caplin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ruszniewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pavel</forename><forename type="middle">M</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2013-10-01">27 September-1 October 2013</date>
			<pubPlace>Amsterdam, Netherlands</pubPlace>
		</imprint>
	</monogr>
	<note>In Paper Presented at The European Cancer Congress</note>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary</title>
		<author>
			<persName><forename type="first">T</forename><surname>Steinmüller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kianmanesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Falconi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="47" to="62" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">ENETS consensus guidelines for the management of bone and bronchial metastases from neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">B</forename><surname>Kos-Kudla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'toole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Falconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="341" to="350" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">The clinical value of [ 90 Y-DOTA]-D-Phe1-Tyr3-octreotide ( 90 Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Waldherr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pless</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Maecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haldemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mueller-Brand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="941" to="945" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [ 90 Y-DOTA]-TOC in metastasized neuroendocrine cancers</title>
		<author>
			<persName><forename type="first">A</forename><surname>Imhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Brunner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Marincek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2416" to="2423" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">Treatment with the radiolabeled somatostatin analog</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kwekkeboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>De Herder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Kam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2124" to="2130" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>]octreotate: toxicity, efficacy, and survival</note>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">Peptide receptor radionuclide therapy with 177 Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin</title>
		<author>
			<persName><forename type="first">M</forename><surname>Van Essen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Krenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Bakker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1219" to="1227" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281</title>
		<author>
			<persName><forename type="first">W</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lipsitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Catalano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="4897" to="4904" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Brizzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berruti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferrero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">388</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumors?</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bajetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Catena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Procopio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="637" to="642" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main">ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Arnold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="326" to="332" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kulke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Scherubl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastrointest Cancer Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="S62" to="S66" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Suppl 2</note>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">Experience in treatment of metastatic pulmonary carcinoid tumors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Granberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wilander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1383" to="1391" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main">Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Strauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sarker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="1106" to="1112" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main">Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">T</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Caplin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="902" to="911" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main">Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Wirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Jänne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Johnson</forename><surname>Be</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="213" to="220" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main">The Akt-mTOR tango and its relevance to cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Hay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="179" to="183" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main">Everolimus for advanced pancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ito</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="514" to="523" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main">Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Hainsworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="2005" to="2012" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main">RAMSETE: a single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wiedenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Capdevila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>suppl; abstr 4122</note>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main">Sunitinib malate for the treatment of pancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">E</forename><surname>Raymond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Raoul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="501" to="513" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main">Activity of sunitinib in patients with advanced neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kulke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Meropol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3403" to="3410" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b173">
	<monogr>
		<title level="m" type="main">PAZONET: a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients ( pts), on behalf of the Spanish Task Force for NETs (GETNE)</title>
		<author>
			<persName><forename type="first">E</forename><surname>Grande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Castellano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>García-Carbonero</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<pubPlace>Vienna</pubPlace>
		</imprint>
	</monogr>
	<note>In Paper Presented at ESMO. Abstract 11570</note>
</biblStruct>

<biblStruct xml:id="b174">
	<analytic>
		<title level="a" type="main">Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Hoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1316" to="1323" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b175">
	<analytic>
		<title level="a" type="main">Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)</title>
		<author>
			<persName><forename type="first">D</forename><surname>Castellano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Capdevila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sastre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="3780" to="3787" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main">Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Earle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="2963" to="2968" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b177">
	<analytic>
		<title level="a" type="main">Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours?</title>
		<author>
			<persName><forename type="first">A</forename><surname>Karpathakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caplin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thirlwell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="R73" to="R92" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main">Long-term follow-up of classical bronchial carcinoid tumors. Clinicopathologic observations</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Warren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Gould</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="125" to="130" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b179">
	<monogr>
		<title level="m" type="main">Central Clinical Hospital of Ministry of Internal Affairs and Administration</title>
		<author>
			<persName><forename type="first">Frederico</forename><surname>Spain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hospital</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><surname>Sírio Libanês</surname></persName>
		</author>
		<author>
			<persName><forename type="first">; Jaroslaw</forename><surname>Brazil</surname></persName>
		</author>
		<author>
			<persName><surname>Cwikla</surname></persName>
		</author>
		<imprint>
			<publisher>Wouter de Herder</publisher>
			<pubPlace>Warsaw, Poland; Netherlands; University of Roma, Italy; Uppsala, Sweden</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Detlief Bartsch, University of Marburg, Germany; Jaume Capdevila, Vall d&apos;Hebron University Hospital ; Erasmus University ; University of</orgName>
		</respStmt>
	</monogr>
	<note>Gianfranco Delle Fave. Barbro Eriksson</note>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Churchill Hospital</title>
		<imprint>
			<publisher>Ashley Grossman</publisher>
		</imprint>
		<respStmt>
			<orgName>Massimo Falconi, University of Milano, Italy; Diego Ferone, University of</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b181">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Tetsuhide</forename><surname>Ito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kyushu</forename><surname>University</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Japan; Robert</forename><surname>Jensen</surname></persName>
		</author>
		<imprint>
			<pubPlace>Bethesda, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>National Institute of Health</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b182">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Gregory</forename><surname>Kaltsas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Beata Kos-Kudla</title>
		<imprint>
			<publisher>Ulrich Knigge</publisher>
		</imprint>
		<respStmt>
			<orgName>National University of Athens, Greece; Fahrettin Kelestimur, Department of Endocrinology &amp; Metabolism, School of Medicine ; Department of Pathopysiology and Endocrinology, Medical University of Silesia</orgName>
		</respStmt>
	</monogr>
	<note>Reza Kianmanesh</note>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Institut Curie</title>
		<imprint/>
		<respStmt>
			<orgName>Eric Krenning, University of Erasmus, Netherlands; Emmanuel Mitry</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Marianne</forename><surname>Nicolson</surname></persName>
			<affiliation>
				<orgName type="collaboration">s Hospital</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Aberdeen</forename><forename type="middle">Royal</forename><surname>Infirmary</surname></persName>
			<affiliation>
				<orgName type="collaboration">s Hospital</orgName>
			</affiliation>
		</author>
		<author>
			<persName><surname>Aberdeen</surname></persName>
			<affiliation>
				<orgName type="collaboration">s Hospital</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">O'connor ;</forename><surname>Uk; Juan</surname></persName>
			<affiliation>
				<orgName type="collaboration">s Hospital</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Dermot</surname></persName>
			<affiliation>
				<orgName type="collaboration">s Hospital</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">St</forename><surname>Toole</surname></persName>
			<affiliation>
				<orgName type="collaboration">s Hospital</orgName>
			</affiliation>
		</author>
		<author>
			<persName><surname>James</surname></persName>
			<affiliation>
				<orgName type="collaboration">s Hospital</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="j">Charite Hospital</title>
		<imprint>
			<publisher>Alexander Fleming Institute</publisher>
		</imprint>
		<respStmt>
			<orgName>St Vincent&apos;s University Hospital &amp; Trinity College</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b185">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Marianne</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Charite</forename><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Germany; John</forename><surname>Berlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Basingstoke</forename><surname>Ramage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Uk; Eric</forename><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><surname>Raymond</surname></persName>
		</author>
		<imprint>
			<pubPlace>Clichy, France, France</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Beaujon University Hospital</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Guido</forename><surname>Rindi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Università</forename><surname>Cattolica-Policlinico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gemelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Andrea Rockall, Imperial Hospital Trust</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<author>
			<persName><forename type="first">Philippe</forename><surname>Ruszniewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Beaujon</forename><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">France; Ramon</forename><surname>Salazar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Institut Català D ´Oncologia (IDIBELL)</title>
				<meeting><address><addrLine>Barcelona, Spain; Verona, Italy; Prague, Czech Republic</addrLine></address></meeting>
		<imprint>
			<publisher>Eva Sedlackova</publisher>
		</imprint>
		<respStmt>
			<orgName>University and Hospital Trust of</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b188">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">; Marie-Pierre</forename><surname>Vullierme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Beaujon</forename><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">France; Wolfgang</forename><surname>Weber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Charite Hospital</title>
		<imprint>
			<publisher>Zeng Zheng-Pei</publisher>
		</imprint>
		<respStmt>
			<orgName>Anders Sundin, Uppsala University Hospital, Sweden; Christos Toumpanakis, Royal Free Hospital ; Chinese Academy of Medical Sciences &amp; Peking Union Medical College</orgName>
		</respStmt>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
